Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of GW685698X 200 mcg Twice Daily, GW685698X 200 mcg and 400 mcg Once Daily in the Morning, and GW685698X 200 mcg and 400 mcg Once Daily in the Evening Compared With Placebo for 8 Weeks in Adolescent and Adult Subjects (12 Years of Age and Older) With Persistent Asthma
Brief Summary: This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.


Options:
A: Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period (From the first dose of the study medication until the Follow-up Visit (up to Study Day 60)); Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, and White Blood Cell Count at 24 Hours Post-dose on Day 1 of Each Treatment Period (Baseline and Day 1 of each treatment period (up to Study Day 54)); Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) at 24 Hours Post-dose on Day 1 of Each Treatment Period (Baseline and Day 1 of each treatment period (up to Study Day 54)); Change From Baseline in Reticulocyte and Red Blood Cell (RBC) Count at 24 Hours Post-dose on Day 1 of Each Treatment Period (Baseline and Day 1 of each treatment period (up to Study Day 54)); Change From Baseline in Hematocrit at 24 Hours Post-dose on Day 1 of Each Treatment Period (Baseline and Day 1 of each treatment period (up to Study Day 54)); Change From Baseline in Mean Corpuscle Volume (MCV) at 24 Hours Post-dose on Day 1 of Each Treatment Period (Baseline and Day 1 of each treatment period (up to Study Day 54)); Change From Baseline in Mean Corpuscle Hemoglobin (MCH) Values at 24 Hours Post-dose on Day 1 of Each Treatment Period (Baseline and Day 1 of each treatment period (up to Study Day 54)); Change From Baseline in Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase (CK) and Gamma Glutamyl Transferase (GGT) Values at 24 Hours Post-dose on Day 1 of Each Treatment Period (Baseline and Day 1 of each treatment period (up to Study Day 54)); Change From Baseline in Albumin and Total Protein at 24 Hours Post-dose on Day 1 of Each Treatment Period (Baseline and Day 1 of each treatment period (up to Study Day 54)); Change From Baseline in Cholesterol, Chloride, Potassium, Sodium, Triglycerides, and Urea at 24 Hours Post-dose on Day 1 of Each Treatment Period (Baseline and Day 1 of each treatment period (up to Study Day 54)); Change From Baseline in Total Bilirubin and Creatinine at 24 Hours Post-dose on Day 1 of Each Treatment Period (Baseline and Day 1 of each treatment period (up to Study Day 54)); Change From Baseline in C-reactive Protein at 24 Hours Post-dose on Day 1 of Each Treatment Period (Baseline and Day 1 of each treatment period (up to Study Day 54)); Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Over the Post-dose 24 Hour (h) Period (Baseline and Day 1 of each treatment period (up to Study Day 54)); Change From Baseline in Heart Rate Over the Post-dose 24 Hour (h) Period (Baseline and Day 1 of each treatment period (up to Study Day 54)); Change From Baseline in Electrocardiographic (ECG) Parameters Over the Post-dose 24 Hour (h) Period (Baseline and Day 1 of each treatment period (up to Study Day 54))
B: The primary efficacy measure will be mean change from baseline at Week 8 (last assessment on treatment using last observation carried forward) in tough (AM or PM pre-dose and pre-rescue bronchodilator) forced expiratory volume in one second (FEV1)
C: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8)
D: Mean Change From Baseline in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at Week 12 (Baseline and Week 12); Change From Baseline in Weighted Mean Serial FEV1 Over 0-24 Hours Post-dose at Week 12 (Baseline and Week 12)

Answer: B